U.S. Markets open in 5 hrs 28 mins

Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
82.17+0.26 (+0.32%)
As of 9:47AM CEST. Market open.
People also watch
Full screen
Previous Close81.91
Bid71.12 x 1000
Ask71.74 x 44000
Day's Range82.10 - 82.52
52 Week Range66.72 - 92.97
Avg. Volume2,417,231
Market Cap100.24B
PE Ratio (TTM)11.37
Earnings DateN/A
Dividend & Yield3.30 (3.50%)
Ex-Dividend Date2017-05-16
1y Target EstN/A
  • Reuters14 hours ago

    FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.

  • Merck's Biosimilar Insulin Gets Tentative FDA Approval
    Zacks3 days ago

    Merck's Biosimilar Insulin Gets Tentative FDA Approval

    Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

  • Reuters4 days ago

    U.S. jury sides with Amphastar over Momenta in drug patent trial

    A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. The verdict by the jury in Boston came in a lawsuit by Cambridge, Massachusetts-based biotechnology company Momenta and its partner, Novartis AG's Sandoz unit, that sought nearly $940 million in damages. The jury found that while Rancho Cucamonga, California-based Amphastar had infringed Momenta's patent, it was invalid and unenforceable.